Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

5 novembre 2018 mis à jour par: MedImmune LLC

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma

The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

584

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Afrique du Sud
      • Durban, Afrique du Sud, 4068
        • Research Site
      • Middelburg, Afrique du Sud, 1055
        • Research Site
      • Pretoria, Afrique du Sud, 0181
        • Research Site
      • Pretoria, Afrique du Sud, 0183
        • Research Site
  • Bulgarie
      • Plovdiv, Bulgarie, 4002
        • Research Site
      • Sofia, Bulgarie, 1431
        • Research Site
      • Sofia, Bulgarie, 1202
        • Research Site
      • Sofia, Bulgarie, 1233
        • Research Site
      • Sofia, Bulgarie, 1750
        • Research Site
      • Sofia, Bulgarie, 1606
        • Research Site
      • Velingrad, Bulgarie, 4600
        • Research Site
  • Hongrie
      • Balassagyarmat, Hongrie, 2660
        • Research Site
      • Budapest, Hongrie, 1125
        • Research Site
      • Budapest, Hongrie, 1529
        • Research Site
      • Budapest, Hongrie, 1033
        • Research Site
      • Csorna, Hongrie, 9300
        • Research Site
      • Debrecen, Hongrie, 4032
        • Research Site
      • Farkasgyepü, Hongrie, 8582
        • Research Site
      • Gödöllő, Hongrie, 2100
        • Research Site
      • Komarom, Hongrie, 2900
        • Research Site
      • Mateszalka, Hongrie, 4700
        • Research Site
      • Nagykanizsa, Hongrie, 8800
        • Research Site
      • Szeged, Hongrie, H-6722
        • Research Site
      • Százhalombatta, Hongrie, 2440
        • Research Site
      • Torokbalint, Hongrie, 2045
        • Research Site
  • Israël
      • Ashkelon, Israël, 78278
        • Research Site
      • Haifa, Israël, 34362
        • Research Site
      • Jerusalem, Israël, 91120
        • Research Site
      • Kfar-Saba, Israël, 44281
        • Research Site
      • Petach Tikva, Israël
        • Research Site
      • Rehovot, Israël, 7661041
        • Research Site
      • Tel Hashomer, Israël, 52621
        • Research Site
  • Japon
      • Chuo-ku, Japon, 103-0028
        • Research Site
      • Chuo-ku, Japon, 103-0027
        • Research Site
      • Chuo-ku, Japon, 104-8560
        • Research Site
      • Fujisawa-shi, Japon, 251-8550
        • Research Site
      • Kiyose-shi, Japon, 204-8585
        • Research Site
      • Kurume-shi, Japon, 830-0011
        • Research Site
      • Maebashi-shi, Japon, 371-0054
        • Research Site
      • Ora-gun, Japon, 370-0615
        • Research Site
      • Sagamihara-shi, Japon, 228-0815
        • Research Site
      • Saitama-Ken, Japon, 338-8553
        • Research Site
      • Sapporo-shi, Japon, 060-0033
        • Research Site
      • Taito-ku, Japon, 111-0051
        • Research Site
      • Toshima-ku, Japon, 171-0014
        • Research Site
      • Yokkaichi-shi, Japon, 510-8567
        • Research Site
  • Lettonie
      • Daugavpils, Lettonie, LV-5401
        • Research Site
      • Rezekne, Lettonie, LV-4600
        • Research Site
      • Riga, Lettonie, 1001
        • Research Site
      • Riga, Lettonie, LV1002
        • Research Site
      • Riga, Lettonie, LV-1038
        • Research Site
      • Riga, Lettonie, LV1010
        • Research Site
  • Lituanie
      • Kaunas, Lituanie, LT50009
        • Research Site
      • Klaipeda, Lituanie, 92288
        • Research Site
      • Klaipeda, Lituanie, 92231
        • Research Site
  • Serbie
      • Belgrade, Serbie, 11000
        • Research Site
      • Kragujevac, Serbie, 34000
        • Research Site
      • Sremska Kamenica, Serbie, 21204
        • Research Site
  • Slovaquie
      • Bardejov, Slovaquie, 085 01
        • Research Site
      • Bratislava, Slovaquie, 84108
        • Research Site
      • Ilava, Slovaquie, 01901
        • Research Site
      • Kosice, Slovaquie, 040 01
        • Research Site
      • Levice, Slovaquie, 934 01
        • Research Site
      • Nove Zamky, Slovaquie, 940 01
        • Research Site
      • Poprad, Slovaquie, 058 01
        • Research Site
      • Spisska Nova Ves, Slovaquie, 052 01
        • Research Site
      • Sturovo, Slovaquie, 94301
        • Research Site
      • Surany, Slovaquie, 94201
        • Research Site
      • Topolcany, Slovaquie, 95501
        • Research Site
      • Zvolen, Slovaquie, 96001
        • Research Site
  • Tchéquie
      • Brandys nad Labem, Tchéquie, 250 01
        • Research Site
      • Hradec Kralove, Tchéquie, 500 05
        • Research Site
      • Mlada Boleslav, Tchéquie, 293 01
        • Research Site
      • Praha 4, Tchéquie, 14059
        • Research Site
      • Praha 8, Tchéquie, 180 81
        • Research Site
      • Praha 8, Tchéquie, 180 00
        • Research Site
      • Strakonice, Tchéquie, 38601
        • Research Site
  • Ukraine
      • Dnipropetrovsk, Ukraine, 49051
        • Research Site
      • Ivano-Frankivsk, Ukraine, 76012
        • Research Site
      • Kyiv, Ukraine, 04050
        • Research Site
      • Kyiv, Ukraine, 02091
        • Research Site
      • Kyiv, Ukraine, 03680
        • Research Site
      • Mykolayiv, Ukraine, 54003
        • Research Site
      • Odessa, Ukraine, 65039
        • Research Site
      • Poltava, Ukraine, 36038
        • Research Site
      • Suprunivka Vil., Poltava Regio, Ukraine, 36028
        • Research Site
      • Vinnytsia, Ukraine, 21029
        • Research Site
      • Zaporizhzhya, Ukraine, 69600
        • Research Site
      • Zaporizhzhya, Ukraine, 69035
        • Research Site
  • États-Unis
    • California
      • Los Angeles, California, États-Unis, 90025
        • Research Site
      • Los Angeles, California, États-Unis, 90048
        • Research Site
    • Florida
      • Miami, Florida, États-Unis, 33133
        • Research Site
      • Oviedo, Florida, États-Unis, 32765
        • Research Site
    • Georgia
      • Savannah, Georgia, États-Unis, 31406
        • Research Site
    • Illinois
      • Peoria, Illinois, États-Unis, 61602
        • Research Site
    • Maryland
      • Baltimore, Maryland, États-Unis, 21224
        • Research Site
    • Minnesota
      • Rochester, Minnesota, États-Unis, 55905
        • Research Site
    • New York
      • New York, New York, États-Unis, 10016
        • Research Site
      • New York, New York, États-Unis, 10029
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, États-Unis, 28277
        • Research Site
      • Charlotte, North Carolina, États-Unis, 28207
        • Research Site
    • Ohio
      • Dublin, Ohio, États-Unis, 43016
        • Research Site
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73120
        • Research Site
    • South Carolina
      • Rock Hill, South Carolina, États-Unis, 29732
        • Research Site
      • Spartanburg, South Carolina, États-Unis, 29303
        • Research Site
    • Texas
      • Houston, Texas, États-Unis, 77070
        • Research Site
    • Virginia
      • Richmond, Virginia, États-Unis, 23220
        • Research Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age 18 through 75
  • Body mass index (BMI) between 18-40 kg/m2 and weight greater than or equal 40 kg
  • Documented physician-diagnosed asthma - Subjects must have received a physician-prescribed asthma controller regimen with medium- or high-dose inhaled corticosteroids (ICS) plus long acting β2 agonist (LABA) -If on asthma controller medications in addition to ICS plus LABA, the dose of the other asthma controller medications (leukotriene receptor inhibitors, theophylline, secondary ICS, long-acting anti-muscarinics (LAMA), cromones, or maintenance oral prednisone or equivalent up to a maximum of 10 mg daily or 20 mg every other day for the maintenance treatment of asthma) must be stable. -Subjects must have a documented history of at least 2 asthma exacerbation events OR at least 1 severe asthma exacerbation resulting in hospitalization within the 12 months prior to first study visit.

Exclusion Criteria:

  • Diagnosis of vocal cord dysfunction, reactive airways dysfunction syndrome, hyperventilation and panic attacks, or other mimics of asthma.
  • Current smokers or subjects with a smoking history of ≥ 10 pack years
  • Former smokers with < 10 pack years must have stopped for at least 1 year to be eligible.
  • Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (eg, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome).
  • Evidence of active liver disease.
  • History of Cancer, except for basal cell carcinoma or insitu carcinoma of the cervix treated with apparent success with curative therapy or other malignancies are eligible provided that curative therapy was completed -Known history of active tuberculosis (TB)
  • History of anaphylaxis to any biologic therapy
  • Positive medical history for hepatitis B or C
  • Subject with human immunodeficiency virus (HIV) or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Placebo
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Médicament: Placebo
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Expérimental: MEDI9929 70 mg
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Médicament: MEDI9929 70 mg
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Expérimental: MEDI9929 210 mg
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Médicament: MEDI9929 210 mg
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Expérimental: MEDI9929 280 mg
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Médicament: MEDI9929 280 mg
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Annualized Asthma Exacerbation Rate (AER) Through Week 52
Délai: Week 0 (Day 1) up to Week 52
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
Week 0 (Day 1) up to Week 52

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Reduction in AER on Subpopulations at Week 52
Délai: Week 52
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Reduction in AER was evaluated in pre-specified subpopulations (blood eosinophil count [eosinophilic and non-eosinophilic], T helper cell 2 [Th2] status [high and low], Fraction of exhaled nitric oxide [FENO] [high and low], serum periostin [high and low], current post bronchodilator forced expiratory volume in 1 second [Post-BD FEV1] reversibility- yes, allergic and non-allergic) of asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up. Also, the high or low was determined using median value.
Week 52
Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Week 52
Délai: Baseline (Week 0 [Day 1]) to Week 52
Forced expiratory volume in 1 second and forced vital capacity measures taken before bronchodilator use were reported.
Baseline (Week 0 [Day 1]) to Week 52
Change From Baseline in FEV1 on Subpopulations at Week 52
Délai: Baseline and up to Week 52
Forced expiratory volume in one second (FEV1) was evaluated in pre-specified subpopulations of asthma. The data presented in the below table for this outcome measure is for pre-bronchodilator FEV1.
Baseline and up to Week 52
Change From Baseline in Post-bronchodilator (Post-BD) FEV1 and FVC at Week 52
Délai: Baseline (Week 0 [Day 1]) to Week 52
Forced expiratory volume in 1 second and forced vital capacity measures taken after bronchodilator use were reported.
Baseline (Week 0 [Day 1]) to Week 52
Change From Baseline in Overall Symptoms Score on Subpopulations at Week 52
Délai: Baseline and up to Week 52
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Overall symptom score is the average of scores of daytime severity, daytime frequency, and nighttime severity symptoms. The daytime frequency and severity items are scored from 0 to 4, where a higher score indicates greater frequency/severity and nighttime severity item is scored from 0 to 4 , where a higher score indicates greater severity. Overall symptom score ranges from 0 to 4, where lower score indicates better asthma symptom while, higher score indicates worse asthma symptom.
Baseline and up to Week 52
Change From Baseline in Asthma Symptoms Measured by Asthma Daily Diary at Week 52
Délai: Baseline (Week 0 [Day 1]) and Week 52
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Symptom score values for night time assessment is 0 (no asthma symptom) to 3 (unable to sleep because of asthma) and symptom score values for day time assessment is 0 (no asthma symptom) to 3 (unable to do normal activities due to asthma). Total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom.
Baseline (Week 0 [Day 1]) and Week 52
Change From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52
Délai: Baseline (Week 0 [Day 1]) and Week 52
The ACQ is a patient-reported questionnaire assessing asthma symptoms (ie, night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) and daily rescue bronchodilator use and FEV1. The ACQ-6 is a shortened version of the ACQ that omits the FEV1 measurement from the original ACQ score. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).
Baseline (Week 0 [Day 1]) and Week 52
Rate of Severe Asthma Exacerbation Through Week 52
Délai: Week 0 (Day 1) up to Week 52
A severe asthma exacerbation is defined as an event that resulted in hospitalization. The severe AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
Week 0 (Day 1) up to Week 52
Time to First Asthma Exacerbation Through Week 52
Délai: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first asthma exacerbation was reported.
Week 0 (Day 1) through Week 52
Time to First Severe Asthma Exacerbation Through Week 52
Délai: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first severe asthma exacerbations (hospitalization) were reported.
Week 0 (Day 1) through Week 52
Number of Participants With at Least One Asthma Exacerbations Through Week 52
Délai: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
Week 0 (Day 1) through Week 52
Number of Participants With at Least One Severe Asthma Exacerbations Through Week 52
Délai: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Participants with severe asthma exacerbations (hospitalization) were reported.
Week 0 (Day 1) through Week 52
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 52
Délai: Baseline (Week 0 [Day 1]) and Week 52
The AQLQ(S) +12 is a 32-item questionnaire that measures the health-related quality of life experienced by asthma participants. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli) scaled on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment).
Baseline (Week 0 [Day 1]) and Week 52
Change From Baseline in European Quality of Life-5 Dimensions 5 Level Version (EQ-5D-5L) Health State Evaluation at Week 52
Délai: Baseline (Week 0 [Day 1]) and Week 52
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1. A higher score indicates better health state. The second component is a self-perceived health score which is assessed using a visual analogue scale (VAS) that ranged from 0 to 100, where 0 indicated the worst health you can imagine and 100 indicated the best health you can imagine.
Baseline (Week 0 [Day 1]) and Week 52
Total Amount of Study Drug Exposure
Délai: Week 0 (Day 1) through Week 52
The total amount of study drug exposure (in milligram) for the entire study period was summarized.
Week 0 (Day 1) through Week 52
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Délai: Day 1 upto Week 64
An adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of medicinal product, whether or not considered related to medicinal product. Serious adverse event is any adverse event that resulted in death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug, for the period until and including the follow-up period (Week 64).
Day 1 upto Week 64
Number of Participants With TEAEs Related to Vital Sign Parameters
Délai: Day 1 upto Week 64
Adverse events observed in participants with clinically significant vital signs abnormalities were assessed.
Day 1 upto Week 64
Number of Participants With TEAEs Related to Clinical Laboratory Evaluation
Délai: Day 1 upto Week 64
An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations of blood and urine samples were performed.
Day 1 upto Week 64
Number of Participants With TEAEs Related to Electrocardiogram Evaluations
Délai: From the start of study drug administration upto Week 64
Adverse events observed in participants with clinically significant electrocardiogram abnormalities were assessed.
From the start of study drug administration upto Week 64
Mean Serum Concentrations of MEDI9929
Délai: Week 0 (Day 1) to Week 64
The mean serum concentrations of MEDI9929 was observed at specified timepoints.
Week 0 (Day 1) to Week 64
Number of Participants With Positive Antibodies to MEDI9929
Délai: Week 0 (Day 1) to Week 64
Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9929. The number of participants with positive serum antibodies to MEDI9929 were presented.
Week 0 (Day 1) to Week 64

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

MedImmune LLC

Collaborateurs

Amgen

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

13 décembre 2013

Achèvement primaire (Réel)

12 décembre 2016

Achèvement de l'étude (Réel)

1 mars 2017

Dates d'inscription aux études

Première soumission

4 décembre 2013

Première soumission répondant aux critères de contrôle qualité

3 février 2014

Première publication (Estimation)

4 février 2014

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 décembre 2018

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2018

Dernière vérification

1 novembre 2018

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • CD-RI-MEDI9929-1146
  • 2013-003269-33 (Numéro EudraCT)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Placebo

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Tunisia

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

3
S'abonner